Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib with Radioactive Iodine in Progressive RAI-Sensitive Differentiated Thyroid Cancer
NCT03506048Phase 2Terminated
- Sponsor
- Emory University
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in differentiated thyroid cancer (DTC), sponsored by Emory University. Primary endpoint: Time To Progression up to 2 years. Started Jan 2019; status: terminated.
02
Drugs
lenvatinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03506048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506048.